SCHEMBL18044873

SCHEMBL18044873

Cc1c(S(=O)(=O)C2CNCCO2)sc(NC(=O)C(C)(C)C)c1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ HPGD P15428 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ ANO1 Q5XXA6 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ CFTR P13569 3/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ AIP O00170 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18044901 0.80 TAAR1 (0.35) ALDH1A1MAPTHPGDSMN1; SMN2NPC1
SCHEMBL18044899 0.79 CFTR (0.51) ALDH1A1KMT2AMAPTHTTMEN1
SCHEMBL18044885 0.62 CFTR (0.43) ALDH1A1MAPTCFTR
SCHEMBL19494899 0.62 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTHTTMEN1
SCHEMBL18044875 0.62 SLC6A3 (0.51) ALDH1A1MAPTCFTR
SCHEMBL18044866 0.61 CFTR (0.36) ALDH1A1MAPTCFTR
SCHEMBL18044883 0.61 CFTR (0.40) ALDH1A1MAPTHPGDCFTR
SCHEMBL16387415 0.60 CFTR (0.50) ALDH1A1KMT2AMAPTHTTMEN1
SCHEMBL18044886 0.60 CFTR (0.48) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL19494287 0.60 KMT2A (0.46) ALDH1A1KMT2AMAPTMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9867806-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2018-01-16 — — US disclosed
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GALAPAGOS NV (BE) 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC3, ABCC5 ALDH1A1 1522/4885KMT2A 3948/4885MAPT 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback